Posaconazole
- Atc Codes:J02AC04
- CAS Codes:171228-49-2
- PHARMGKB ID:171228-49-2
Table of contents
- Brand Names
- Drug Combinations
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Unlabeled Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Inhibits
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Noxafil, Posaconazole (d); Belgium: Noxafil; Czech Republic: Noxafil, Posaconazole (d); Denmark: Noxafil; Estonia: Noxafil; Finland: Noxafil; France: Noxafil; Germany: Noxafil, Posaconazole (d); Greece: Noxafil; Hungary: Noxafil, Posaconazole (d); Ireland: Noxafil; Italy: Noxafil; Latvia: Noxafil; Lithuania: Noxafil; Luxembourg: Noxafil, Posaconazole (d); Malta: Noxafil, Posaconazole (d); Netherlands: Noxafil, Posaconazole (d); Poland: Noxafil, Posaconazole (d); Portugal: Noxafil, Posaconazole (d); Romania: Noxafil, Posaconazole (d); Slovakia: Noxafil; Slovenia: Noxafil; Spain: Noxafil; Sweden: Noxafil, Posaconazole (d); UK: Noxafil.
North America
Canada: Posanol; USA: Noxafil.
Drug combinations
Posaconazole, Mometasone, and Orbifloxacin
Chemistry
Posaconazole: C~37~H~42~F~2~N~8~O~4~. Mw: 700.78. (1) 3H-1,2,4-Triazol-3-one, 4-[4-[4-[4-[[5-(2,4-difluorophenyl)tetrahydro-5-(1H-1,2,4-triazol-1-ylmethyl)-3-furanyl]methoxy]phenyl]-1-piperazinyl]phenyl]-2-(1-ethyl-2-hydroxypropyl)-2,4-dihydro-, [3R-[3α(1S*,2S*),5α]]-; (2) 4-[p-[4-[p-[[(3R,5R)-5-(2,4-Difluorophenyl)tetrahydro-5-(1H-1,2,4-triazol-1-ylmethyl)-3-furyl]methoxy]phenyl]-1-piperazinyl]phenyl]-1-[(1S,2S)-1-ethyl-2-hydroxypropyl]-Δ^2^-1,2,4-triazolin-5-one. CAS-171228-49-2 (1999).
Pharmacologic Category
Antifungals; Azoles. (ATC-Code: J02AC04).
Mechanism of action
Interferes with fungal cytochrome P450 (latosterol-14α-demethylase) activity, decreasing ergosterol synthesis and inhibiting fungal cell membrane formation.
Therapeutic use
Prophylaxis of invasive Aspergillus and Candida infections in severely-immunocompromised patients. Treatment of oropharyngeal candidiasis (including patients refractory to itraconazole and/or fluconazole).
Pregnancy and lactiation implications
Teratogenic in animal studies. There are no adequate, well-controlled studies in pregnant women. Use only if benefit to mother justifies potential risk to fetus during pregnancy or breast-feeding.
Unlabeled use
Salvage therapy of refractory invasive fungal infections. Mucormycosis.
Contraindications
Hypersensitivity to posaconazole or any component of the formulation. Co-administration of cisapride, ergot alkaloids, pimozide, quinidine, or sirolimus.
Warnings and precautions
Use with caution in hypersensitivity to other azole antifungal agents (cross-reaction may occur). Hepatic dysfunction occurred (use with caution in hepatic impairment). Use caution in increased risk of arrhythmia (concurrent QTc-prolonging drugs, hypokalemia). Breakthrough fungal infections in severe diarrhea or vomiting might occur. Use caution in severe renal impairment. Levels of cyclosporine may significantly increase if used concomitantly with posaconazole and may result in rare serious adverse events (e.g. nephrotoxicity, leukoencephalopathy, and death). High potential for interactions in patients receiving drugs that decrease absorption or increase metabolism of posaconazole.